40 / 40
•
BRCAmut is the best biomarker to predict the highest benefit of PARP inhibitors
•
HRD tests can select patients BRCAwt with a longer PFS, but PARP inhibitors can
benefit any patient with HGSOC independently of biomarkers
•
Olaparib, Niraparib and Rucaparib improve PFS significantly as maintenance after
platinum in BRCAmut patients, and to a lesser extent in BRCAwt patients
•
There are a class toxicity of PARP inhibitors: asthenia, anemia, and nausea
•
With Niraparib, in patients <77 Kg or <150.000 platelets it is recommended a
starting dose of 200 mg/day to reduce the risk of thrombocitopenia
•
Rucaparib needs to be monitored for possible hepatotoxicity
•
There is a sinergy between PARP inhbitors and immunotherapy or antiangiogenic,
pending to confirm in phase III studies
Maintenance with PARP inhibitors in ovarian cancer
Take home messages